SOCIETY OF HEMATOLOGIC ONCOLOGY
SOHO 2025September 3-6, 2025 Houston, Texas, USA
N. Poster
Poster title
Applicant name
Status
 |
|
|
|
| ALL-017 | Global Heterogeneity of Pediatric Acute Lymphoblastic Leukemia Central Nervous System Diagnostics | Laura Almási |  Received |
 |
|||
| IBCL-056 | Impact of Total Lesion Glycolysis (TLG) in Predicting Response of Follicular Lymphoma to Rituximab | Paul-Emile Pignot | Received |
|
|||
| MCL-88 | Using Artificial Intelligence to Overcome Resistance to CAR-T Therapy in Mantle Cell Lymphoma | Fangfang Yan | Received |
|
|||
| AML-117 | A Phase 1b Study of Selinexor and Venetoclax in Patients With Relapsed or Refractory Acute Myeloid Leukemia | Somedeb Ball | Received |
|
|||
| AML-142 | A Rare Case of Acute Aleukemic Mast Cell Leukemia With Osteoblastic Lesions in the Appendicular Skeleton | Muralidhar Idamakanti | Received |
|
|||
| AML-150 | A Phase 1b/2 Trial of an All-Oral Triplet Regimen for IDH-Mutated Myeloid Malignancies: Decitabine or Cedazuridine and Venetoclax in Combination with Ivosidenib or Enasidenib | Jennifer Marvin-Peek | Received |
|
|||
| CML-161 | Achieving Treatment-Free Remission in CML Patients Treated With Bosutinib: Data From the ITALY-TFR Registry | Carmen Fava | Received |
|
|||
| AML-179 | The Role of Interim Bone Marrow Assessments in Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis | Yuanli Lei | Received |
|
|||
| TCL-189 | Outcomes of Patients With Anaplastic Large Cell Lymphoma Who Relapse Post-Brentuximab Vedotin | Jonathan Weiss | Received |
|
|||
| MM-190 | The Impact of Forced Internal Displacement Due to the Full-Scale Russian Invasion of Ukraine on Survival and Quality of Life for Multiple Myeloma Patients: A Real-World Observational Study | Tetiana Lymanets | Received |
|
|||
| ABCL-198 | Pre-Phase Rituximab and High-Dose Methotrexate Enables Reassessment of Intensive Treatment Eligibility in Frail Patients with Central Nervous System Lymphoma: A Multicenter Cohort Study | Richard I. Lewis | Received |
|
|||
| HL-201 | Pembrolizumab in Relapsed/Refractory Hodgkin Lymphoma: Institutional Experience at a High-Complexity Oncologic Center in Colombia | MARIA PAOLA SPIRKO | Received |
|
|||
| MPN-202 | JAK Inhibitors vs Best Available Therapy for Myelofibrosis: A Meta-Analysis of Randomized Clinical Trials | Junaid Anwar | Received |
|
|||
| MM-208 | Trends in Multiple Myeloma and Cardiovascular Disease-Related Mortality (19992023): Analysis of the CDC WONDER Database | Sai Sushrutha Mudupula Vemula | Received |
|
|||
| AML-229 | Efficacy and Safety of Pivekimab Sunirine (PVEK) in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) in the CADENZA Study. | Elaine Abernathy | Received |
|
|||
| MDS-249 | Outcomes With Imetelstat by Serum Erythropoietin (sEPO) Levels in Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Who Were Treatment Naive or Who Had Prior Treatment With Erythropoiesis-Stimulating Agents (ESAs) | Jessica Conte | Received |
|
|||
| MM-259 | Impact of the International Myeloma Working Group (IMWG) SLiM Criteria on Multiple Myeloma Management: A Tertiary Care Center Experience | Dhairya Gor | Received |
|
|||
| CT-262 | A Randomized Phase 3 Trial in Patients with Hematologic Malignancies Demonstrates Improved Survival Free of Chronic GVHD with Orca-T Compared to Conventional Allogeneic Hematopoietic Stem Cell Transplant | Rawan Faramand | Received |
|
|||
| HL-297 | Brentuximab Vedotin-Induced Pulmonary Toxicities in Hodgkin Lymphoma Patients | Nagah Elmusharaf | Received |
|
|||
| MDS-306 | The Future of Care for Myelodysplastic Syndromes (MDS): An AI-Driven Multidisciplinary Virtual Clinical Panel | David Swoboda | Received |
|
|||
| MDS-307 | Acquired Platelet Dysfunction Secondary to Myelodysplastic Syndrome: Successful Resolution With Syndrome-Directed Therapy | Amy Hockman | Received |
|
|||
| MDS-330 | Outcomes of Imetelstat Therapy in Patients With Ring Sideroblast-Negative (RS-) Lower-Risk Myelodysplastic Syndromes (LR-MDS) From the Pooled IMerge Study Populations | Jessica Conte | Received |
|
|||
| MPN-332 | IMpactMF, Randomized, Open-Label, Phase 3 Trial of Imetelstat Versus Best Available Therapy (BAT) in Patients With Intermediate-2 (INT-2) or High-Risk (HR) Myelofibrosis Relapsed or Refractory (R/R) to Janus Kinase Inhibitors (JAKi) | Jessica Conte | Received |
|
|||
| IBCL-341 | Fixed-Duration Subcutaneous Mosunetuzumab in Patients With Previously Untreated High-Tumor Burden Follicular Lymphoma (FL): Interim Results From the Phase 2 MorningSun Study | Max Regan | Received |
|
|||
| CML-342 | Efficacy and Safety of Asciminib Compared With Other TKIs in CML: Meta-Analysis of Controlled Studies and Descriptive Review of Single-Arm Cohorts | Fatih Burak Kaner | Received |
|
|||
| ALL-346 | Impact of Patient Profiles on Hematologist-Oncologists Preferences for Treating Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph ALL) Using Tyrosine Kinase Inhibitors (TKI) in Combination With Chemotherapy: A Discrete Choice Experiment | Ajibade Ashaye | Received |
|
|||
| MM-353 | Trial in Progress: Phase 2 SubQSA Study of Subcutaneous (SC) Isatuximab (Isa) Administered by an On-Body Delivery System (OBDS) in Combination With Weekly Carfilzomib and Dexamethasone (Kd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) | Jessica Maddaluna | Received |
|
|||
| ABCL-360 | Clinical, Economic, and Humanistic Outcomes of First-Line High-Risk Large B-Cell Lymphoma: A Series of Systematic Literature Reviews | Evan Popoff | Received |
|
|||
| MDS-379 | X Chromosome Inactivation Uncovers Age-Related Clonal Hematopoiesis and Hematologic Traits in Colombian Elderly Women | Oscar Tavera | Received |
|
|||
| AML-388 | Phase 1b Study of Menin-KMT2A Inhibitor Bleximenib in Combination With Intensive Chemotherapy (IC) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) with KMT2Ar or NPM1 Alterations | Jessica Gallon | Received |
|
|||
| AML-391 | Acute Myeloid Leukemia Outcomes in a Referral Oncology Hospital: Spotlight on Therapy-Related AML | Marcela de Souza Simes | Received |
|
|||
| MPN-395 | Predictors of Response to Second-Line Momelotinib After Ruxolitinib Failure: An Independent Cooperative Study | Chiara Sartor | Received |
|
|||
| ABCL-400 | A Philippine First | Glofitamab for Refractory Diffuse Large B-Cell Lymphoma After Multiple Treatment Failures: A Case Report and Literature Review | Jan Miko Aaron Baybay | Received |
|
|||
| MM-405 | Optec/Optal: A Phase 2 Study to Evaluate Outpatient (OP) Step-Up Administration of Teclistamab (Tec) or Talquetamab (Tal) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM) | Susan Hoekstra | Received |
|
|||
| ABCL-408 | Prognostic Value of Lymphocyte-to-Monocyte Ratio in Diffuse Large B-Cell Lymphoma: A Retrospective Study From Pakistan | Sehrish Sarwar Baloch | Received |
|
|||
| AML-412 | Bleximenib Dose Optimization and Determination of the Recommended Phase 2 Dose (RP2D) From a Phase 1 Study in Patients With Relapsed/Refractory Acute Leukemia (AL) With KMT2A and NPM1 Alterations | Jessica Gallon | Received |
|
|||
| AML-418 | Recommended Phase 2 Dose (RP2D) Determination of Bleximenib in Combination With VenetoclaxAzacitidine (VENAZA): Phase Ib Study in Newly Diagnosed (ND) and Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) With KMT2A or NPM1 Alterations | Jessica Gallon | Received |
|
|||
| AML-420 | Phase I Trial of Azacitidine, Venetoclax, and Allogeneic NK Cells in Acute Myeloid Leukemia (ADVENT-AML): Results From Dose-Escalation Phase | Joseph Vasquez | Received |
|
|||
| CML-426 | Outcomes of Patients with Blast Phase Chronic Myeloid Leukemia Following Ponatinib-Based Therapy | Omer Karrar | Received |
|
|||
| IBCL-427 | Impact of a Short-Format Medical Education on Clinicians Knowledge and Competence in CAR T-Cell Therapy for B-Cell Lymphomas | Emilie Desse | Received |
|
|||
| MM-430 | Impact of a Short-Form, Case-Based Continuing Medical Education on Clinician Knowledge and Competence in Optimizing CD38 Antibody-Based Triplet Regimens for Early-Relapse Multiple Myeloma | Emilie Desse | Received |
|
|||
| MM-434 | Identifying Circulating Tumor Cells via Advanced Flow Cytometry as Emerging Prognostic Indicators in Patients With Asymptomatic Monoclonal Gammopathies | Giannakas konstantinos | Received |
|
|||
| MM-435 | Sequential Whole-Body Magnetic Resonance Imaging for Evaluating Treatment Response in Patients With Newly Diagnosed Multiple Myeloma | Erasmia Boutakoglou | Received |
|
|||
| MM-441 | The Efficacy and Safety of Cilta-Cel and Ide-Cel in Relapsed/Refractory Multiple Myeloma: A Meta-Analysis | Ahmad Iftikhar | Received |
|
|||
| ALL-469 | Impact of Delayed Chemotherapy Initiation in Adult Acute Lymphoblastic Leukemia: A Real-World Multicenter Cohort Study Across the United States | Yu-Han Chen | Received |
|
|||
| CML-473 | Treatment-Free Remission (TFR) in Chronic-Phase Chronic Myeloid Leukemia (CP-CML): Analysis of Predictive Factors and Novel Scoring System for Molecular Recurrence | Alessandro Laganŕ | Received |
|
|||
| AML-474 | &947;9&948;2 T-Cell Activation With ICT01 and Azacitidine-Venetoclax (Aza-Ven) Induces High Rates of Complete Remission (CR) in Newly Diagnosed (ND) Acute Myeloid Leukemia (AML): Preliminary Results of the Phase 1/2 Study EVICTION | Abhishek Maiti | Received |
|
|||
| ABCL-475 | 5-Year Analysis of the POLARIX Study: Prolonged Follow-Up Confirms Positive Impact of Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (Pola-R-CHP) on Outcomes | Max Regan | Received |
|
|||
| MPN-476 | Prognostic Impact of Early Spleen Response in Polycythemia Vera Patients Treated With Ruxolitinib: A Real-World Cooperative Study | Chiara Sartor | Received |
|
|||
| IBCL-482 | Fixed-Duration Subcutaneous Mosunetuzumab (Mosun SC) Leads to High Rates of Durable Responses, Low Rates of Cytokine Release Syndrome (CRS), and Non-Inferior Exposure Compared With Intravenous Administration in Patients With Relapsed/Refractory (R/R) Follicular Lymphoma (FL): Primary Analysis of a Pivotal Phase II Study | Max Regan | Received |
|
|||
| MM-486 | Impact of Early vs Delayed Antiretroviral Therapy on Mortality in HIV-Positive Patients With Multiple Myeloma: A Real-World Cohort Analysis | Krishna Doshi | Received |
|
|||
| ABCL-487 | Hybrid Deep Learning Approaches for Mortality Prediction in Non-Hodgkin Lymphoma: A Comparative Analysis | Krishna Doshi | Received |
|
|||
| AML-488 | A Phase 1 Study of Gemtuzumab Ozogamicin Added to Cytarabine, Daunorubicin, and Midostaurin Induction in Newly Diagnosed FLT3-Mutated Acute Myeloid Leukemia | Jayanshu Jain | Received |
|
|||
| MDS-493 | Cardiovascular Risk Factors Exhibit Differential Effects in Patients With Myelodysplastic Neoplasms (MDS) vs Non-Cancer Controls | Diego Adrianzen Herrera | Received |
|
|||
| AML-509 | Clinical Experience with HDAC Inhibitor-Based Protocols in MECOM-Rearranged Acute Myeloid Leukemia | Eitan Kugler | Received |
|
|||
| AML-517 | Characterization of Immunophenotypic Changes Following Menin Inhibition in Acute Myeloid Leukemia | Georgina El Hajjar | Received |
|
|||
| ABCL-522 | Patient Outcome Variation in Aggressive B-Cell Non-Hodgkin Lymphoma Based on Regional Proximity to Cancer Treatment Center in Central Missouri | Phyo Thazin Myint | Received |
|
|||
| MPN-524 | Phase 3 Study Comparing Ropeginterferon Alfa-2b With Anagrelide As Second-Line Treatment for Essential Thrombocythemia: SURPASS-ET Trial | Lucia Masarova | Received |
|
|||
| ABCL-528 | Efficacy and Safety of Bridging Zanubrutinib Regimen With Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Systematic Review and Meta-Analysis | Shubhangi Sharma | Received |
|
|||
| AML-534 | Superior Preclinical Efficacy of BRG1/BRM Inhibitor Combined With BET Inhibitor or Decitabine Against MECOM-rearranged (MECOM-r) Acute Myeloid Leukemia (AML) | Warren Fiskus | Received |
|
|||
| MDS-541 | Association Between Somatic Mutation Burden and Anemia Severity in Lower-Risk Myelodysplastic Syndromes: A Cross-Sectional Analysis From an Indian Cohort | Madhavi Nallewar | Received |
|
|||
| ABCL-544 | Glofitamab Plus Gemcitabine and Oxaliplatin (Glofit-GemOx) in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): 2 Year Follow-Up of the Phase 3 STARGLO Trial | Max Regan | Received |
|
|||
| MCL-553 | Glofitamab Induces High Response Rates and Durable Remissions in Patients With Heavily Pretreated Relapsed/Refractory (R/R) Mantle Cell Lymphoma (MCL), Including Those With a Poor Prognosis: Subgroup Results From a Phase 1/2 Trial | Max Regan | Received |
|
|||
| MM-554 | Ex Vivo Testing Platform Unveils Differential Response to Daratumumab and Isatuximab in Multiple Myeloma | Gerardo Gatti | Received |
|
|||
| MDS-557 | Concurrent Clonal Hematopoiesis Mutations in advanced solid tumors prior to chemotherapy exposure: A Retrospective Study | Monika Kulasekaran | Received |
|
|||
| AML-559 | ASXL1 Mutations in AML Are Associated With a Distinct Epigenetic State That Results in Vulnerabilities to Epigenetic-Targeted Agents | Christopher Mill | Received |
|
|||
| ALL-562 | Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Cumulative Dose | Matthew Winn | Received |
|
|||
| CLL-563 | Bexobrutideg (NX-5948), a Novel Brutons Tyrosine Kinase Degrader, Demonstrates Rapid and Durable Clinical Responses in Relapsed/Refractory Chronic Lymphocytic Leukemia: Updated Findings from an Ongoing Phase 1a Study | Lee Miller | Received |
|
|||
| MPN-574 | Bezuclastinib Expanded Access Program for Patients with Systemic Mastocytosis | Emily Plummer | Received |
|
|||
| CML-575 | ENABLE: A Phase 1a/1b Study of ELVN-001, a Selective Active Site Inhibitor of BCR::ABL1, in Patients With Previously Treated Chronic Myeloid Leukemia | Helen Collins | Received |
|
|||
| IBCL-576 | Long-term follow-up of the Phase 2 ELM-2 study: Efficacy and survival outcomes with odronextamab in relapsed/refractory follicular lymphoma | Megan McConnell | Received |
|
|||
| HL-582 | Clinical and Translational Responses to Plinabulin, Radiation, and Anti-PD-1 in Relapsed Refractory Classical Hodgkin Lymphoma | June Lu | Received |
|
|||
| CML-586 | Effect of TERN-701 on Transporter and Cytochrome P450 Probe Substrates and the Effect of Acid-Reducing Agents on TERN-701 Pharmacokinetics | Kace Anderson | Received |
|
|||
| ALL-589 | Post Hoc Analysis of MRD Negativity After End of Induction in the Phase 3 PhALLCON Trial | Sean ODonnell | Received |
|
|||
| CML-592 | Characterization and Efficacy of TERN-701 in Pre-Clinical Models of Chronic Myeloid Leukemia | Ben Parson | Received |
|
|||
| MPN-594 | Clinical and Gene Expression Patterns Associated With Disease Progression in Patients With Low-Risk Myelofibrosis Enrolled in the Myelofibrosis and Essential Thrombocythemia Observational Study (MOST) | Kristina Cunillera | Received |
|
|||
| ALL-597 | Outcomes in Patients With B-Cell Precursor Acute Lymphoblastic Leukemia Receiving Inotuzumab Ozogamicin Stratified by Body Mass Index | Matthew Winn | Received |
|
|||
| ABCL-599 | Patient Perceptions of Treatment Options for Diffuse Large B-Cell Lymphoma in the United States: A Social Media Listening Study | Sara Ali | Received |
|
|||
| MPN-605 | JAK2V617F VAF and Presence of Copy Neutral-LOH at Chromosome 9p Predicts Transformation to Myelofibrosis in Patients With Polycythemia Vera Enrolled in REVEAL | Kristina Cunillera | Received |
|
|||
| CT-610 | Combining ModalitiesProgressive Muscle Relaxation Delivered via Virtual Realitya Feasibility Trial in Cellular Therapy Patients | Swathi Somisetty | Received |
|
|||
| CLL-623 | Outcomes of Patients With Concurrent Chronic Lymphocytic Leukemia and Non-Small Cell Lung Carcinoma | Corbin Wright | Received |
|
|||
| AML-626 | Real-World Safety Profile of Isocitrate Dehydrogenase (IDH)-1 Inhibitors: A Pharmacovigilance Comparison of Olutasidenib and Ivosidenib Utilizing the FDA Adverse Event Reporting System (FAERS) | Aneta Strumilowska | Received |
|
|||
| ALL-636 | Ponatinib Monotherapy Following Combination With Chemotherapy in Patients With Newly Diagnosed Ph ALL: Phase 3 PhALLCON Post Hoc Subgroup Analysis | Sean ODonnell | Received |
|
|||
| MDS-639 | Treatment and Transplant Outcomes of Concurrent Clonal Lymphoid and Myeloid Neoplasms: A Case Series | Jenna Laidley | Received |
|
|||
| CML-641 | Efficacy, Safety, and End-of-Treatment Mutational Results in Patients With Chronic-Phase Chronic Myeloid Leukemia: 5-Year Follow-Up of the Phase 2 OPTIC Study | Sean ODonnell | Received |
|
|||
| CT-654 | From Response Rates to Toxicity Profiles: A Meta-Analysis of Two FDA Approved CAR-T Therapies in Relapsed/Refractory Multiple Myeloma2025 | Prakhyath Srikaram | Received |
|
|||
| CLL-655 | Clinical Significance and Treatment Outcomes of Pleural Effusion in Chronic Lymphocytic Leukemia | Kire Lau | Received |
|
|||
| TCL-661 | Clinical Profiles and Outcomes of Mature T-Cell Lymphomas in Adult Filipino Patients: Insights From a Tertiary Hospital Experience | Justine Lorenz Natividad | Received |
|
|||
| MDS-673 | PKM and PKLR mRNA Expression in CD34 Cells Derived From Patients With Myelodysplastic Syndromes | Corrinne Segal | Received |
|
|||
| ABCL-674 | A Phase 1 Trial of NX-2127, a First-in-Class BTK Dual-Targeted Protein Degrader, in Patients With Relapsed/Refractory B-cell Malignancies | Lee Miller | Received |
|
|||
| IBCL-675 | Bexobrutideg (NX-5948), a Novel Brutons Tyrosine Kinase (BTK) Degrader, Shows High Clinical Activity and Tolerable Safety in an Ongoing Phase 1a/b Study in Patients With Waldenström Macroglobulinemia (WM) | Lee Miller | Received |
|
|||
| MPN-678 | Anemia Burden in Patients With Myelofibrosis Treated With a JAK Inhibitor: Data From the Optum Market Clarity Database | Idoroenyi Amanam | Received |
|
|||
| ALL-679 | Clinical Profile, Treatment, and Outcomes of Febrile Neutropenia in Acute Leukemias | Eskedar Ferdu Azerefegne | Received |
|
|||
| IBCL-684 | Clinical outcomes according to baseline comorbidities and age in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with the bispecific antibody (bsAb) odronextamab in the Phase 2 ELM-2 study | Megan McConnell | Received |
|
|||
| CT-694 | Real-World Healthcare Resource Utilization (HCRU) Following Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) in New Authorized Treatment Centers in the US | Evan Popoff | Received |
|
|||
| CT-708 | Systematic Literature Review of Clinical, Economic, and Health-Related Quality of Life Outcomes in Real-World Evidence of Second-Line or Higher Relapsed/Refractory Large B-Cell Lymphoma Patients Treated With Axicabtagene Ciloleucel | Pardis Lakzadeh | Received |
|
|||
| CLL-710 | Early Outcomes of a Treatment Access Program for Patients With Chronic Lymphocytic Leukemia in Armenia, Ethiopia, and Nepal | Andrielle Yost | Received |
|
|||
| MPN-714 | Allogeneic Transplant Outcomes in Myelofibrosis in the Era of Novel JAK Inhibitors: A Single-Institution Experience | Georgio Medawar | Received |
|
|||
| ALL-716 | Treatment Patterns of Asciminib in Philadelphia Chromosome-Positive (Ph) Acute Lymphoblastic Leukemia (ALL): A Retrospective Cohort Analysis | David Wei | Received |
|
|||
| MM-718 | Lisaftoclax (APG-2575) Combined With Novel Therapeutic Regimens in Patients With Relapsed or Refractory (R/R) Multiple Myeloma (MM) or Immunoglobulin Light-Chain (AL) Amyloidosis | Paul Fletcher | Received |
|
|||
| ALL-724 | First-in-Human Study of Asciminib Monotherapy in Adults With Relapsed/Refractory (R/R) Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph ALL) | Michael Mauro | Received |
|
|||
| MCL-725 | Efficacy of Rituximab-Bendamustine With or Without Acalabrutinib in Patients With Untreated, High-Risk Mantle Cell Lymphoma: An Analysis of the Phase 3 ECHO Trial | Kelly Montenegro | Received |
|
|||
| ABCL-728 | Rapid Ramp-Up Dosing of Bispecific Antibodies in Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) | Yucai Wang | Received |
|
|||
| MDS-730 | Overall Survival (OS) and Duration of Red Blood Cell-Transfusion Independence (RBC-TI) for First-Line Erythropoiesis-Stimulating Agent (ESA)-Naive Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated With Luspatercept (LUSPA) vs Epoetin Alf | Guillermo Garcia-Manero | Received |
|
|||
| AML-732 | Ziftomenib Combined With Intensive Induction Chemotherapy (73) in Newly Diagnosed NPM1-m or KMT2A-r Acute Myeloid Leukemia (AML): Updated Phase 1a/b Results From KOMET-007 | Katherine Dodson | Received |
|
|||
| ABCL-734 | Ongoing Phase 3 waveLINE-010 Study of Zilovertamab Vedotin (ZV) Plus R-CHP Versus R-CHOP in Participants With Untreated Diffuse Large B-Cell Lymphoma (DLBCL) | Madison Sumatra | Received |
|
|||
| ABCL-740 | Baseline Metabolic Tumor Volume (MTV) as a Prognostic Marker in Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Relapsed/Refractory Large B-Cell Lymphoma | Masooma Rana | Received |
|
|||
| MDS-742 | Rethinking PNH Flow Cytometry Requests: A Decade of Misutilization and Missed Diagnostic Yield | Osman Radhwi | Received |
|
|||
| AML-743 | Phase 1b/2 Study of Lisaftoclax (APG-2575) Combined With Azacitidine in Patients With Newly Diagnosed (ND) or Prior Venetoclax-Exposed Myeloid Malignancies | Paul Fletcher | Received |
|
|||
| MPN-746 | Single- and Multiple-Ascending Doses of DISC-3405, a Recombinant Humanized Antibody Targeting TMPRSS6, Increased Hepcidin and Reduced Iron and Hematocrit in Healthy Volunteers | Marcus Carden | Received |
|
|||
| CLL-750 | Safety and Treatment-Free Outcomes of Ibrutinib-Based Regimens in Relapsed/Refractory Chronic Lymphocytic Leukemia: A Systematic Review and Meta-Analysis | Nikhilendhar Nag Mopuru | Received |
|
|||
| MPN-752 | Efficacy of Pacritinib vs Momelotinib in Patients With Thrombocytopenic Myelofibrosis: A Matching Adjusted Indirect Treatment Comparison | Gauri Saal | Received |
|
|||
| CML-754 | Improved Patient-Reported Outcomes (PROs) With Asciminib vs Investigator-Selected Tyrosine Kinase Inhibitors (IS-TKIs) in Newly Diagnosed Chronic Myeloid Leukemia (CML): ASC4FIRST Week 48 PROs Analysis | Ghayas Issa | Received |
|
|||
| MPN-757 | A Phase 1b Trial of DISC-0974, an Anti-Hemojuvelin Antibody, in Patients With Myelofibrosis and Anemia | Emily Herod | Received |
|
|||
| ABCL-758 | Updated Safety Run-In Results From LOTIS-5: A Phase 3, Randomized Trial of Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Patients With R/R DLBCL/HGBL | Dana Lackner | Received |
|
|||
| CML-766 | Primary Endpoint Results of the Phase 3b ASC4START Trial of Asciminib vs Nilotinib in Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML-CP): Time to Treatment Discontinuation Due to Adverse Events (TTDAE) | Stephen Strickland | Received |
|
|||
| IBCL-770 | Matching-Adjusted Indirect Comparison of Epcoritamab With Rituximab Lenalidomide Versus Tafasitamab With Rituximab Lenalidomide in Second-Line or Later Follicular Lymphoma | Jennifer Pearsall | Received |
|
|||
| CLL-773 | Real-World Outcomes of BTK Inhibitors (BTKi) in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Patients With Preexisting Cardiovascular Comorbidities | Ramsay Hafer | Received |
|
|||
| ALL-774 | Safety and Efficacy of AZD0486 in Adolescent and Adult Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia: Early Results From the Phase 1/2 SYRUS Study | Kelly Montenegro | Received |
|
|||
| ABCL-777 | Initial Results From LOTIS-7: A Phase 1b Study of Loncastuximab Tesirine Plus Glofitamab in Patients With Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL) | Dana Lackner | Received |
|
|||
| MPN-780 | Safety and Efficacy of Bromodomain and Extra-Terminal (BET) Inhibitor INCB057643 in Patients With Relapsed or Refractory Myelofibrosis (MF) and Other Advanced Myeloid Neoplasms: A Phase 1 Study | Zoe Sand | Received |
|
|||
| IBCL-783 | High CR and MRD Negativity Rates With GLPG5101, a Fresh, Stem-Like, Early Memory CD19 CAR T With 7-Day Vein-to-Vein Time: Full Results From ATALANTA-1 Cohort 3 (iNHL) | Steven Jones | Received |
|
|||
| MPN-785 | Results From VERIFY, an International, Randomized, Phase 3, Double-Blind, Placebo-Controlled Study of Rusfertide (First-in-Class Hepcidin Mimetic) for Treatment of Polycythemia Vera (PV) | Anthony DiLauro | Received |
|
|||
| AML-789 | Ziftomenib in Relapsed/Refractory NPM1-Mutant Acute Myeloid Leukemia: Phase 1b/2 Results From the Pivotal KOMET-001 Study | Eliza Norrell | Received |
|
|||
| MPN-794 | Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor-Naive Patients With Myelofibrosis: 72-Week Follow-Up With Long-Term Efficacy Outcomes of the Phase 3 Manifest-2 Study | Pavel Kramata | Received |
|
|||
| AML-795 | First-in-Human Study of Autologous Chimeric Engulfment Receptor T Cell CER-1236 Targeting TIM-4-L in Acute Myeloid Leukemia (CertainT-1) | Abhishek Maiti | Received |
|
|||
| CML-801 | Increased Healthcare Costs With Concomitant Acid-Reducing Agents and Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: A US Payer Perspective | Carlton Anderson | Received |
|
|||
| ABCL-808 | The Tissue is the Issue: Primary Amyloidosis in a Lymphoma Patient | Issac Flores | Received |
|
|||
| ABCL-810 | Population-Level Impact of CAR-T Approval on Diffuse Large B-Cell?Lymphoma Mortality: A CDC WONDER, Age-Stratified, Difference-in-Differences Analysis | Woo Joo Lee | Received |
|
|||
| TCL-816 | Survival Trends in T-cell Lymphomas in the Era of Novel Therapies: A National Cancer Database (NCDB) Study | Yucai Wang | Received |
|
|||
| ABCL-817 | Real-World Outcomes of Frontline Polatuzumab and Impact of Frailty in Older Adults With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL): A Multicenter Study | Jessica Chicola | Received |
|
|||
| MDS-823 | Impact of Clonal Hematopoiesis on Clinical Outcomes in Melanoma Patients Treated With Immune Checkpoint Inhibitors | Mason Alford-Holloway | Received |
|
|||
| ABCL-825 | P53 Expression Correlates With Worse Outcomes in a Cohort of Large B-Cell Lymphoma | Coen Lap | Received |
|
|||
| AML-828 | Prognostic Impact and Clinical Outcomes of IDH1/IDH2 Mutations in Newly Diagnosed Acute Myeloid Leukemia Treated With Hypomethylating Agents and Venetoclax | Jayda Esplund | Received |
|
|||
| TCL-834 | Progression-Free Survival and Overall Survival in Relapsed/Refractory T-cell Lymphoma Patients on Chemotherapy vs Targeted Therapy | Omar Alzarkali | Received |
|
|||
| MDS-848 | Cost-Per-Responder Analysis of Iptacopan Versus Eculizumab and Ravulizumab in Treatment of Paroxysmal Nocturnal Hemoglobinuria: Implications for Decision-Making | Stacy Van Scoten | Received |
|
|||
| ALL-852 | Retrospective Analysis of Hepatotoxicity Associated With Inotuzumab Therapy in B-Cell Acute Lymphoblastic Leukemia: Describing a New Clinical Phenomenon Called Calicheamicin Syndrome | Derek Tai | Received |
|
|||
| MPN-854 | Comparative Outcomes and Toxicities of Treosulfan vs Busulfan-Based Myeloablative Conditioning in Allogeneic Hematopoietic Stem Cell Transplantation | Fatima Ali | Received |
|
|||
| AML-858 | Incidence and Screening Patterns of Central Nervous System Involvement in Acute Myeloid Luekemia Patients Treated With Hypomethylating Agents and Venetoclax in the Frontline Setting | Kateryna Fedorov | Received |
|
|||
| ALL-860 | Incidence and Characteristics of Venous Thromboembolism in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Systematic Review | Roha Saeed Memon | Received |
|
|||
| CT-866 | Impact of Sociodemographic Factors on Conditioning Intensity and Outcomes of Hematopoietic Cell Transplant Recipients With Myeloid Malignancies | Allison O. Taylor | Received |
|
|||
| MPN-867 | Intriguing Effect of Myeloproliferative Neoplasms on Pregnancy Outcomes: A Comprehensive Propensity Matched Multicenter Retrospective Analysis | Nikhil Vojjala | Received |
|
|||
| MPN-874 | CPX-351 in Combination With Ruxolitinib for the Treatment of Myeloproliferative Neoplasm-Accelerated/Blast Phase | Shivani Handa | Received |
|
|||
| MM-878 | Risk of Therapy-Related Myeloid and Lymphoid Neoplasms in Patients With Multiple Myeloma With Lenalidomide Exposure: Retrospective Multicenter Analysis Using the TrinetX Database | Nikhil Vojjala | Received |
|
|||
| MDS-882 | A Phase 2 Study of Ianalumab in Patients With Primary Immune Thrombocytopenia Previously Treated With at Least Two Lines of Therapy (VAYHIT3) | Stacy Van Scoten | Received |
|
|||
| IBCL-884 | Zanubrutinib Dosing and Mutational Status Impact Response and Outcomes in Waldenström Macroglobulinemia | Alberto Guijosa | Received |
|
|||
| MM-913 | Defining Gene Expression Programs of Amyloidogenic Clonal Plasma Cells Characterized by Single-Cell B-Cell Receptor and Transcriptomic Profiling | Xuezhu Wang | Received |
|
|||
| CML-920 | Treatment-Free Remission in Chronic Myeloid Leukemia With Rare ABL1 Gene Fusions | Delphine REA | Received |
|
|||
| HL-923 | Treatment-Related Cardiotoxicity in Patients With Malignant lymphoma: A 5-Year Follow-Up | Farjah Alqahtani | Received |
|
|||
| ABCL-924 | Epidemiological Profile and Outcomes of Patients With Diffuse Large B-Cell Lymphoma in a Brazilian Public Tertiary Care Center | Carolina Ribeiro de Castro Pires | Received |
|
|||
| CML-937 | Efficacy and Safety of Asciminib in Patients With Chronic-Phase Chronic Myeloid Leukemia After One Tyrosine Kinase Inhibitor: An Interim Analysis of the Phase 2 ASC2ESCALATE Trial | Koji Sasaki | Received |
|
|||
| AML-941 | Trends in Acute Myeloid Leukemia-Related Mortality Among Patients With Sepsis (19992023): A CDC WONDER Database Analysis | Sai Sushrutha Mudupula Vemula | Received |
|
|||
| CT-945 | Low Rates of High-Grade Toxicities With GLPG5101, a Fresh, Stem-Like, Early Memory Phenotype Anti-CD19 CAR T-Cell Therapy With a 7-Day Vein-to-Vein Time in Patients With Non-Hodgkin Lymphoma in the ATALANTA-1 Study | Steven Jones | Received |
|
|||
| MDS-951 | Pharmacokinetic/Pharmacodynamic Analysis of Elritercept in Phase 2 Studies Shows Efficacy in Anemia Treatment for Lower-Risk Myelodysplastic Neoplasms and Myelofibrosis | Kayleigh Corbet-Adams | Received |
|
|||
| CT-954 | Intradermal Vididencel Vaccination in Measurable Residual Disease-Positive Acute Myeloid Leukemia Patients Results in Increased Antigen-Presenting Cells and T Cells at the Injection Site and Local Immune-Cell Interactions | ystein Sefland | Received |
|
|||
| TCL-955 | Frontline Brentuximab Vedotin and CHP in Patients With Peripheral T-cell Lymphoma With 10 CD30 Expression: Primary Analysis Results From the Phase 2 SGN35-032 Study | Matthew Winn | Received |
|
|||
| CML-969 | Impact of Adverse Events (AEs) on Health-Related Quality of Life (HRQOL) in Chronic Myeloid Leukemia (CML): Results From the Patient Survey on Humanistic Burden of Intolerance to First or Second Tyrosine Kinase Inhibitors (TKIs) SHIFT Study in the US | Kelly Schoenbeck | Received |
|
|||
| AML-976 | V-RULES: Impact of Treatment Setting on CPX-351 Safety and Effectiveness in Secondary Acute Myeloid Leukemia | Molly McEvoy | Received |
|
|||
| MPN-980 | Cytopenia Is Associated With Real-World Disease Progression and Diminished Survival in Patients With Myelofibrosis: Analysis of a U.S. National Administrative Claims Database | Sarah Hague | Received |
|
|||
| CML-981 | A Multinational Study to Explore Patient Preferences for Chronic Myeloid Leukemia Treatments | Anastasia Goussarova | Received |
|
|||
| AML-983 | Evaluating ChatGPTs Responses to Commonly Asked Questions in Allogeneic Hematopoietic Stem Cell Transplantation: A Physician-Based Assessment | SAFA AFRIDI | Received |
|
|||
| MPN-993 | Clinical Outcomes in Patients With Myelofibrosis Treated With Ruxolitinib and Anemia-Supporting Medications | Zoe Sand | Received |
|
|||
| AML-995 | QuANTUM-Wild: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in FLT3-ITDNegative Acute Myeloid Leukemia | Peyton Little | Received |
|
|||
| MPN-999 | A Study to Evaluate Single-Agent Selinexor Versus Physicians Choice in Participants With Previously Treated Myelofibrosis | Kim Dobson | Received |
|
|||
| MDS-1006 | Survival Benefit and Resource Utilization of First-Line Treatment With Luspatercept vs First-Line Erythropoiesis-Stimulating Agents for Lower-Risk Myelodysplastic Syndromes: Results of Model Simulation | Ahmed Hnoosh | Received |
|
|||
| CT-1018 | Clinical and Economic Outcomes of Inpatient and Outpatient Chimeric Antigen Receptor T-Cell (CAR-T) Therapy in Newly Authorized Treatment Centers (ATCs) in the US | Kelly Birch | Received |
|
|||
| TCL-1020 | Combination Durvalumab and Lenalidomide Shows Superior Efficacy vs Single-Agent Durvalumab in Refractory/Advanced Cutaneous T-Cell Lymphoma in a Randomized Phase 2 Trial | Christiane Querfeld | Received |
|
|||
| MM-1024 | US MM-6 Subgroup Analysis by Race/Ethnicity, Renal Function, and Area Income of In-Class Transition (iCT) From Parenteral Bortezomib (V) to Oral Ixazomib in Newly Diagnosed Multiple Myeloma (NDMM) | Ruemu E. Birhiray | Received |
|
|||
| HL-1025 | Circulating Tumor DNA (ctDNA) Assessment in Patients With Early-Stage Classical Hodgkin Lymphoma (cHL) Treated With a Combination of Brentuximab Vedotin (BV) and Nivolumab | Matthew Winn | Received |
|
|||
| MDS-1026 | Real-World Healthcare Resource Utilization Among Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) in the United States | Stacy Van Scoten | Received |
|
|||
| CML-1030 | Quality of Life and Work Impacts Among Caregivers of Patients With Chronic Myeloid Leukemia: A Caregiver Survey in the US | Kelly Schoenbeck | Received |
|
|||
| MDS-1048 | A Single-Institution Experience of Iptacopan in Paroxysmal Nocturnal Hemoglobinuria | Stacy Van Scoten | Received |
|
|||
| MDS-1056 | Outcomes of Hypomethylating Agent-Based Therapy in Patients With Myelodysplastic Syndrome With Fibrosis | Abigail Huetteman | Received |
|
|||
| IBCL-1066 | ELARA Phase 2 Clinical Outcomes for Tisagenlecleucel in Patients With High-Risk Relapsed/Refractory Follicular Lymphoma: 4-Year Update | Katelyn Kim | Received |
|
|||
| MM-1070 | Ciltacabtagene Autoleucel (Cilta-cel) vs Standard of Care (SOC) in Patients (Pts) with Relapsed/Refractory Multiple Myeloma (MM): CARTITUDE-4 Survival Subgroup Analyses | Amanda Blevins | Received |
|
|||
| ABCL-1076 | Estimating the Survival Impact of Not Receiving Chimeric Antigen Receptor T-cell (CAR-T) Therapy When Eligible in Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL) Patients in the US | Giuseppe Bonetti | Received |
|
|||
| MM-1081 | Absolute Lymphocyte Count as a Key Biomarker for Monitoring Safety After Ciltacabtagene Autoleucel | Amanda Blevins | Received |
|
|||
| MM-1089 | Matching Efficacy and Safety in Clinical Trials vs Real-World Studies of Teclistamab in Relapsed/Refractory Multiple Myeloma | Aliza Dulal | Received |
|
|||
| ABCL-1093 | Rapcabtagene Autoleucel (YTB323) Phase 2 Trial in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL): Clinical Update | Katelyn Kim | Received |
|
|||
| ABCL-1094 | Rising Mortality Due to Non-Hodgkin Lymphoma Among Adults in the United States | Krupa Savani | Received |
|
|||
| ABCL-1097 | Primary Bone Diffuse Large B-Cell Lymphoma (DLBCL) Is a Rare but Benign Entity in Comparison With Nodal DLBCL | Balint Varnai | Received |
|
|||
| ABCL-1103 | Analyzing the Outcomes of Adults With Diffuse Large B-Cell Lymphoma Following Admission for Non-ST-Elevation Myocardial Infarction | Krupa Savani | Received |
|
|||
| CML-1107 | Asciminib Demonstrates Comparable Tolerability and Efficacy With Once-Daily (QD) and Twice-Daily (BID) Dosing in Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Final Analysis (Week 72) of the Phase 3b AIM4CML Trial | Moshe Levy | Received |
|
|||
| ABCL-1113 | Safety and Efficacy of AZD0486, a CD19CD3 T-Cell Engager, in Relapsed or Refractory Diffuse Large B-Cell Lymphoma | Kelly Montenegro | Received |
|
|||
| ABCL-1118 | Durability of Complete Responses in Patients From the ECHELON-3 Study | Matthew Winn | Received |
|
|||
| ABCL-1119 | Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Glofitamab or Rituximab Plus Gemcitabine and Oxaliplatin in Patients With Transplant-Ineligible Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis | Jennifer Pearsall | Received |
|
|||
| AML-1123 | Characterization of an Oral Oncology Drug Repository Program for Hematology and Hematopoietic Cell Transplant Patients at a Comprehensive Cancer Center | Allyson Waller | Received |
|
|||
| AML-1127 | TRILLIUM: A Phase 2 Multicenter Trial of Tagraxofusp Plus Venetoclax and Azacitidine (VEN/AZA) in Patients Ineligible for Intensive Chemotherapy (IC) With Previously Untreated CD123 Acute Myeloid Leukemia (AML) | Kelsi Bates | Received |
|
|||
| ABCL-1137 | Trends and Disparities in Non-Hodgkin Lymphoma Mortality in the United States, 19992021 | Lay She Ng | Received |
|
|||
| MM-1139 | Safety and Efficacy of Teclistamab in the Management of Relapsed/Refractory Multiple Myeloma: A Meta-Analysis | Jerry Qi | Received |
|
|||
| MDS-1141 | APPULSE-PNH: Oral Iptacopan Monotherapy Demonstrates Clinically Meaningful Hemoglobin (Hb) Increases in Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH) and Hb =10 g/dL on Anti-C5 Therapy | Stacy Van Scoten | Received |
|
|||
| CT-1147 | Hybrid Academic/Community Cellular Therapy Program, Adverse Events, and Outcomes After CAR-T Therapy in Hematological Malignancies, Including Outpatient Experience: A Retrospective Chart Review | Haven Curtis | Received |
|
|||
| AML-1164 | Geriatric Assessment-Based Fitness Helps Genetic Profile to Determine Outcomes in Older Acute Myeloid Leukemia Patients | Pilar Lancho-Lavilla | Received |
|
|||
| HL-1166 | Malnutrition Severity Predicts Clinical Outcomes in Hodgkin Lymphoma: Evidence From a Nationwide Cohort | Ahmad Basharat | Received |
|
|||
| AML-1174 | Survival Outcomes and Health-Related Quality of Life in Older Adults With Acute Myeloid Leukemia | GABRIELA RODRIGUEZ MACIAS | Received |
|
|||
| MDS-1181 | Epidemiological Insights Into Chronic Myelomonocytic Leukemia: A Real-World Evidence Study Using the TriNetX Network | Ahmad Basharat | Received |
|
|||
| MCL-1191 | Genetic Prognostic Markers in Mantle Cell Lymphoma | Nadezhda Nemstsveridze | Received |
|
|||
| CT-1192 | Characterization of Infectious Complications Following CAR T-Cell Therapy and the Need for Antibiotic Treatment During the Expected Period of Cytokine Release Syndrome | Patrick Crorkin | Received |
|
|||
| MPN-1218 | Ruxolitinib and Interferon Alfa Induce Superior Rates of Complete Peripheral Blood Count Remission Compared With Anagrelide in Hydroxyurea-Exposed Essential Thrombocythemia | Andrew Srisuwananukorn | Received |
|
|||
| ALL-1222 | Trends in Leukemia-Related Mortality With Concurrent Mycoses: CDC WONDER Analysis (19992020) | Abdelrahman Mohamed | Received |
|
|||
| ABCL-1224 | Updated Results From EPCORE NHL-6: Phase 2 Study of Subcutaneous Epcoritamab as Outpatient Treatment for 2L Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) | Kristina Aguilera | Received |
|
|||
| ABCL-1228 | CNS Prophylaxis in DLBCL and HGBCL: Comparing Intrathecal, High-Dose Methotrexate, and Combination Strategies | Graham Parker | Received |
|
|||
| MDS-1233 | Real-World Treatment Patterns and Outcomes of Luspatercept in Treatment-Naďve Patients With Lower-Risk Myelodysplastic Syndromes (LR-MDS) in a Large US Community Oncology Practice | Amanda Warner | Received |
|
|||
| ABCL-1269 | Prognostic Value of the Endothelial Activation and Stress Index (EASIX) Score in Newly Diagnosed Patients with Diffuse Large B-Cell Lymphoma: A Retrospective Single-Health System Study | Riyan Bittar | Received |
|
|||
| MM-1270 | Alcohol Use and Risk of Renal, Infectious, and Hematologic Complications in Multiple Myeloma: A Real-World Cohort Study | Syed Pasha | Received |
|
|||
| AML-1277 | Anti-Tumor Activity and Restoration of Hematopoiesis Achieved With Tagraxofusp in Patients With Treatment-Naďve Blastic Plasmacytoid Dendritic Cell Neoplasm: Pivotal Trial Subanalysis | Kelsi Bates | Received |
|
|||
| IBCL-1286 | Langerhans Cell Histiocytosis: A Retrospective Analysis Using the SEER Database | Shammas Bajwa | Received |
|
|||
| AML-1290 | Outcomes in Patients Younger Than 50 Years Old (yo) With Treatment-Naive Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Treated With Tagraxofusp: Subanalysis of a Phase 1/2 Trial | Kelsi Bates | Received |
|
|||
| ABCL-1305 | Risk of Diabetic Ketoacidosis and Hyperosmolar Hyperglycemic Syndrome in Lymphoma: A Real-World Comparison of Diffuse Large B-Cell Lymphoma and Follicular Lymphoma in Diabetic Patients | Syed Pasha | Received |
|
|||
| MDS-1306 | Survival Trends and Prevalence Disparities in Refractory Anemia With Ringed Sideroblasts | Shammas Bajwa | Received |
|
|||
| AML-1310 | Subgroup Analysis by Fitness Criteria of Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm Treated With First-Line Tagraxofusp | Kelsi Bates | Received |
|
|||
| TCL-1324 | Clinical Characteristics and Outcomes of Secondary Hemophagocytic Lymphohistiocytosis: A Five-Year Single-Center Experience | Maha Hameed | Received |
|
|||
| AML-1325 | Temporal Trends in Septicemia Mortality Among Patients With Myeloid Leukemia in the United States during 19992020: Insight From the CDC WONDER Database | Abdelrahman Mohamed | Received |
|
|||
| ABCL-1331 | Renal Risk Differences Between Diffuse Large B-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: A Real-World Retrospective Study | Syed Pasha | Received |
|
|||
| MM-1339 | Novel Therapies in Intermediate- and High-Risk Smoldering Multiple Myeloma: A Scoping Review | Maha Hameed | Received |
|
|||
| IBCL-1350 | Stagnant Survival in Older Adult Patients With Peripheral T-Cell Lymphoma: A SEER-Based Analysis (20002015) | Syed Pasha | Received |
|
|||
| AML-1357 | Outcomes in Acute Myeloid Leukemia With MECOM Rearrangement (MECOMr-AML) Treated With Hypomethylating Agent Plus Venetoclax | Leora Boussi | Received |
|
|||
| ALL-1362 | Frequency and Predictors of Cardiovascular Mortality in Acute Lymphoblastic Leukemia: Insights From the Surveillance, Epidemiology, and End Results (SEER) Database | Ahmad Iftikhar | Received |
|
|||
| TCL-1383 | CXCL9 as a Biomarker in Adults With Malignancy-Associated Hemophagocytic Lymphohistiocytosis | Jason Krastein | Received |
|
|||
| MPN-1385 | Trends and Disparities in Renal Disease-Related Mortality Among Adults With Myeloproliferative Neoplasms in the US | Abdelrahman Mohamed | Received |
|
|||
| MM-1395 | Immune Reconstitution, Vaccine Protection, and Infectious Complications Following BCMA-Targeted CAR-T Therapy in Relapsed/Refractory Multiple Myeloma | Maria Moscvin | Received |
|
|||
| ABCL-1407 | Split-Dose R-CHOP With Interim De-Escalation of Therapy in Elderly Patients With Diffuse Large B-cell Lymphoma | Nirav Shah | Received |
|
|||
| CT-1412 | Infection Risk in CAR-T Therapy Versus Bispecific Antibodies in B-Cell Lymphoma: A Systematic Review and Meta-Analysis | Herman van Besien | Received |
|
|||
| AML-1449 | Hypoxia-Inducible Factor-1 Alpha in Acute Myeloid Leukemia: A Systematic Review of Contemporary Evidence on Prognostic Significance and Therapeutic Potential | Dhruvi modi | Received |
|
|||
| ABCL-1462 | Comparing Deep Learning and Traditional Models for Predicting Survival in DLBCL: DeepSurv vs CoxPH | Ameya Kasture | Received |
|
|||
| MDS-1488 | Allogeneic Stem Cell Transplant with Myeloablative Fractionated Busulfan-, Fludarabine-, and Thiotepa-Conditioning Regimen in Older Patients With High-Risk MDS | Mark Tanner | Received |
|
|||
| ABCL-1492 | Mosunetuzumab Plus Polatuzumab Vedotin (M-Pola) is Superior to Rituximab Plus Gemcitabine and Oxaliplatin (R-GemOx) in Autologous Stem Cell Transplant (ASCT)-Ineligible Patients With Relapsed/Refractory (R/R) Large B-cell Lymphoma (LBCL): Primary Results of the Phase 3 SUNMO Trial | Max Regan | Received |
|
|||
| MCL-1493 | Fixed-Duration Outpatient Subcutaneous Mosunetuzumab Polatuzumab Vedotin Shows Robust Efficacy in a Phase 2 Study of Relapsed/Refractory (R/R) Post-BTK Inhibitor Mantle Cell Lymphoma (MCL) | Max Regan | Received |
|
|||
| IBCL-1494 | MorningSun: Open-Label Phase 2 Trial of the Efficacy and Safety of Subcutaneous Mosunetuzumab as Frontline Treatment in Symptomatic Patients with Marginal Zone Lymphoma (MZL) | Max Regan | Received |
|
|||
| CT-1498 | A Global Phase 1B Study of JNJ-90014496, A CD19/CD20 Bi-Specific Chimeric Antigen Receptor (Car) T-Cell Therapy, in Patients (Pts) With Relapsed/Refractory (R/R) Large B-Cell Lymphoma (LBCL) | Jessica Gallon | Received |
|
|||
SOHO 2025
September 3-6, 2025 Houston, Texas, USA
Search and consult posters online
in an exclusive section
for each poster
in an exclusive section
for each poster
ACTIVE FROM 03/09/2027 TO 03/09/2027
Poster
Gallery
Gallery
Upload
Poster
Poster
Featured Poster
Vote poster
Poster Discussion
Forum
Forum
|
Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress.
|
|
||
|
||||
|
|
